Diagnostic test maker Meridian Bioscience‘s (NYSE:VIVO) Chief Executive Jack Kraeutler received a 3 percent increase in compensation this year to $843,000.
Here’s how Kraeutler’s 2011 compensation breaks down, according to a recent regulatory filing: $546,000 in base salary; $228,000 in stock awards and $69,000 in “other” compensation, which includes retirement contributions, auto allowance and financial planning.
Unlike most CEOs, Kraeutler was not his organization’s highest-paid employee. That distinction went to William Motto, the company’s executive chairman, who was paid $885,000 in 2011. Motto is Meridian’s founder and has been chairman of the company’s board since 1977, according to the regulatory document.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
For its fiscal year ended in September 2011, Meridian reported a 12 percent increase in sales to $160 million, and a 1 percent increase in profits to $27 million.
Earlier this week, Meridian announced that it had received U.S. regulatory approval to begin selling a new Clostridium difficile test.
